TFAM and hepatocellular carcinoma: In recent years, targeted and immunotherapy have made rapid progress, and molecules that affect HCC recurrence and metastasis have been continuously discovered, such as, Trigger receptor expressed on myeloid cells-2(TREM2) deficiency increased the therapeutic effect of anti-programmed death ligand-1(PD-L1) blockade by enhancing antitumor activity of CD8+ T cells (13), mitochondrial transcription factor A(TFAM) may serve as an effective target to block HCC metastasis.